EHC

SEC source: 0001127602-23-007402 · form4.xml · nonDerivative · entry 1

COLTHARP DOUGLAS E · CIK 0001186879 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,963

F1 · shares: These shares were withheld or surrendered to pay the insider's tax withholding obligations incurred in connection with the vesting of the related restricted stock.

SEC source: 0001127602-23-007400 · form4.xml · nonDerivative · entry 1

Charbonneau Elissa Joy · CIK 0001647458 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,881.061

F1 · shares: These shares were withheld or surrendered to pay the insider's tax withholding obligations incurred in connection with the vesting of the related restricted stock.

SEC source: 0001127602-23-006976 · form4.xml · nonDerivative · entry 2

Tarr Mark J · CIK 0001304057 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 502,546

F2 · shares: Annual award of restricted stock pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-23-006976 · form4.xml · nonDerivative · entry 1

Tarr Mark J · CIK 0001304057 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 485,722

F1 · shares: This issuance of restricted stock is the result of the satisfaction of certain performance criteria set out in the terms of a performance share unit award made on February 24, 2021.

SEC source: 0001127602-23-006974 · form4.xml · nonDerivative · entry 2

COLTHARP DOUGLAS E · CIK 0001186879 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,803

F2 · shares: Award of restricted stock pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-23-006974 · form4.xml · nonDerivative · entry 1

COLTHARP DOUGLAS E · CIK 0001186879 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,217

F1 · shares: This issuance of restricted stock is the result of the satisfaction of certain performance criteria set out in the terms of a performance share unit award made on February 24, 2021.

SEC source: 0001127602-23-006972 · form4.xml · nonDerivative · entry 2

Darby John Patrick · CIK 0001664699 · EVP, Gen Counsel & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,014

F2 · shares: Award of restricted stock pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-23-006972 · form4.xml · nonDerivative · entry 1

Darby John Patrick · CIK 0001664699 · EVP, Gen Counsel & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,286

F1 · shares: This issuance of restricted stock is the result of the satisfaction of certain performance criteria set out in the terms of a performance share unit award made on February 24, 2021.

SEC source: 0001127602-23-006970 · form4.xml · nonDerivative · entry 2

Charbonneau Elissa Joy · CIK 0001647458 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,237.061

F2 · shares: Annual award of restricted stock pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-23-006970 · form4.xml · nonDerivative · entry 1

Charbonneau Elissa Joy · CIK 0001647458 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,265.061

F1 · shares: This issuance of restricted stock is the result of the satisfaction of certain performance criteria set out in the terms of a performance share unit award made on February 24, 2021.

SEC source: 0001127602-23-006968 · form4.xml · nonDerivative · entry 2

Fay Edmund · CIK 0001433234 · Sr. Vice Pres. and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 98,851

F2 · shares: Annual award of restricted stock pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-23-006968 · form4.xml · nonDerivative · entry 1

Fay Edmund · CIK 0001433234 · Sr. Vice Pres. and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,288

F1 · shares: This issuance of restricted stock is the result of the satisfaction of certain performance criteria set out in the terms of a performance share unit award made on February 24, 2021.

SEC source: 0001127602-23-006965 · form4.xml · nonDerivative · entry 2

Price Andrew L · CIK 0001475399 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,176

F2 · shares: Annual award of restricted stock pursuant to the Corporation's 2016 Omnibus Performance Incentive Plan.

SEC source: 0001127602-23-006965 · form4.xml · nonDerivative · entry 1

Price Andrew L · CIK 0001475399 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,450

F1 · shares: This issuance of restricted stock is the result of the satisfaction of certain performance criteria set out in the terms of a performance share unit award made on February 24, 2021.

SEC source: 0001127602-23-006550 · form4.xml · nonDerivative · entry 1

Charbonneau Elissa Joy · CIK 0001647458 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,356.061

F1 · shares: These shares were withheld or surrendered to pay the insider's tax withholding obligations incurred in connection with the vesting of the related restricted stock.

SEC source: 0001127602-23-006548 · form4.xml · nonDerivative · entry 1

Tarr Mark J · CIK 0001304057 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 424,219

F1 · shares: These shares were withheld or surrendered to pay the insider's tax withholding obligations incurred in connection with the vesting of the related restricted stock.

SEC source: 0001127602-23-006544 · form4.xml · nonDerivative · entry 1

COLTHARP DOUGLAS E · CIK 0001186879 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,315

F1 · shares: These shares were withheld or surrendered to pay the insider's tax withholding obligations incurred in connection with the vesting of the related restricted stock.

SEC source: 0001127602-23-006539 · form4.xml · nonDerivative · entry 1

Fay Edmund · CIK 0001433234 · Sr. Vice Pres. and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,163

F1 · shares: These shares were withheld or surrendered to pay the insider's tax withholding obligations incurred in connection with the vesting of the related restricted stock.

SEC source: 0001127602-23-006531 · form4.xml · nonDerivative · entry 1

Darby John Patrick · CIK 0001664699 · EVP, Gen Counsel & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,487

F1 · shares: These shares were withheld or surrendered to pay the insider's tax withholding obligations incurred in connection with the vesting of the related restricted stock.

SEC source: 0001127602-23-006535 · form4.xml · nonDerivative · entry 1

Price Andrew L · CIK 0001475399 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,062

F1 · shares: These shares were withheld or surrendered to pay the insider's tax withholding obligations incurred in connection with the vesting of the related restricted stock.

SEC source: 0001127602-23-004939 · form4.xml · derivative · entry 4

COLTHARP DOUGLAS E · CIK 0001186879 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Encompass Health Common Stock · 17,895 shares

Expires 2023-02-21

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The exercise price and number of options reported have been adjusted, pursuant to Article 17 of the 2016 Omnibus Performance Incentive Plan, for the spin-off distribution of the common stock of Enhabit, Inc.

F2 · derivative.underlying_shares: The exercise price and number of options reported have been adjusted, pursuant to Article 17 of the 2016 Omnibus Performance Incentive Plan, for the spin-off distribution of the common stock of Enhabit, Inc.

SEC source: 0001127602-23-004939 · form4.xml · nonDerivative · entry 2

COLTHARP DOUGLAS E · CIK 0001186879 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,097

F1 · price: This per share price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.78 to $60.84, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-23-004939 · form4.xml · nonDerivative · entry 1

COLTHARP DOUGLAS E · CIK 0001186879 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,992

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001127602-23-001755 · form4.xml · nonDerivative · entry 1

Williams Terrance · CIK 0001798480 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,092

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 17, 2023, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $61.16. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-23-001753 · form4.xml · nonDerivative · entry 1

CORRELL DONALD L · CIK 0001199794 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 96,479

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 17, 2023, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $61.16. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-23-001751 · form4.xml · nonDerivative · entry 1

CARMICHAEL GREG D · CIK 0001247734 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,568

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 17, 2023, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $61.16. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-23-001749 · form4.xml · nonDerivative · entry 1

SCHLICHTING NANCY M · CIK 0001376358 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,038

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 17, 2023, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $61.16. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-23-001747 · form4.xml · nonDerivative · entry 1

Maryland Patricia Anne · CIK 0001798468 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,738

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 17, 2023, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $61.16. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-23-001745 · form4.xml · nonDerivative · entry 2

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,096

F2 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 17, 2023, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $61.16. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-23-001745 · form4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,101

F1 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2022 to defer fixed percentages of their directors fees for 2023. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the dividend of $0.15 per share paid on January 17, 2023.

SEC source: 0001127602-23-001743 · form4.xml · nonDerivative · entry 1

KATZ LESLYE G · CIK 0001193884 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,032

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 17, 2023, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $61.16. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-23-001741 · form4.xml · nonDerivative · entry 1

O'Connor Kevin J. · CIK 0001808321 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,969

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 17, 2023, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $61.16. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-23-001739 · form4.xml · nonDerivative · entry 1

HERMAN JOAN E · CIK 0001248398 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,032

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 17, 2023, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $61.16. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-23-001737 · form4.xml · nonDerivative · entry 2

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 157,007

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2022 to defer fixed percentages of their directors fees for 2023. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly deferral and the dividend of $0.15 per share paid on January 17, 2023.

F3 · price: This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $61.65 to $61.66, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.

SEC source: 0001127602-23-001737 · form4.xml · nonDerivative · entry 1

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 156,325

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On January 17, 2023, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $61.16. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-23-000510 · form4.xml · nonDerivative · entry 1

COLTHARP DOUGLAS E · CIK 0001186879 · EVP & Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,097

F1 · shares: These shares were withheld or surrendered to pay the insider's tax withholding obligations incurred in connection with the vesting of the related restricted stock.

F2 · balance_after: The total share holdings reported in this column include the adjustment of outstanding restricted stock awards, pursuant to Article 17 of the 2016 Omnibus Performance Incentive Plan, for the spin-off distribution of the common stock of Enhabit, Inc.

SEC source: 0001127602-23-000503 · form4.xml · nonDerivative · entry 1

Price Andrew L · CIK 0001475399 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 66,360

F1 · shares: These shares were withheld or surrendered to pay the insider's tax withholding obligations incurred in connection with the vesting of the related restricted stock.

F2 · balance_after: The total share holdings reported in this column include the adjustment of outstanding restricted stock awards, pursuant to Article 17 of the 2016 Omnibus Performance Incentive Plan, for the spin-off distribution of the common stock of Enhabit, Inc.

SEC source: 0001127602-23-000493 · form4.xml · nonDerivative · entry 1

Darby John Patrick · CIK 0001664699 · EVP, Gen Counsel & Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,856

F1 · shares: These shares were withheld or surrendered to pay the insider's tax withholding obligations incurred in connection with the vesting of the related restricted stock.

F2 · balance_after: The total share holdings reported in this column include the adjustment of outstanding restricted stock awards, pursuant to Article 17 of the 2016 Omnibus Performance Incentive Plan, for the spin-off distribution of the common stock of Enhabit, Inc.

SEC source: 0001127602-23-000488 · form4.xml · nonDerivative · entry 1

Fay Edmund · CIK 0001433234 · Sr. Vice Pres. and Treasurer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 92,441

F1 · shares: These shares were withheld or surrendered to pay the insider's tax withholding obligations incurred in connection with the vesting of the related restricted stock.

F2 · balance_after: The total share holdings reported in this column include the adjustment of outstanding restricted stock awards, pursuant to Article 17 of the 2016 Omnibus Performance Incentive Plan, for the spin-off distribution of the common stock of Enhabit, Inc.

SEC source: 0001127602-23-000479 · form4.xml · nonDerivative · entry 1

Tarr Mark J · CIK 0001304057 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 426,319

F1 · shares: These shares were withheld or surrendered to pay the insider's tax withholding obligations incurred in connection with the vesting of the related restricted stock.

SEC source: 0001127602-23-000485 · form4.xml · nonDerivative · entry 1

Charbonneau Elissa Joy · CIK 0001647458 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,688.061

F1 · shares: These shares were withheld or surrendered to pay the insider's tax withholding obligations incurred in connection with the vesting of the related restricted stock.

F2 · balance_after: The total share holdings reported in this column include the adjustment of outstanding restricted stock awards, pursuant to Article 17 of the 2016 Omnibus Performance Incentive Plan, for the spin-off distribution of the common stock of Enhabit, Inc.

SEC source: 0001127602-22-024569 · form4.xml · nonDerivative · entry 1

CARMICHAEL GREG D · CIK 0001247734 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,546

SEC source: 0001127602-22-024170 · form4.xml · nonDerivative · entry 2

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,085

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2021 to defer fixed percentages of their directors fees for 2022. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly deferral and the dividend of $0.15 per share paid on October 17, 2022.

SEC source: 0001127602-22-024168 · form4.xml · nonDerivative · entry 2

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 156,101

F2 · shares: The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2021 to defer fixed percentages of their directors fees for 2022. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly deferral and the dividend of $0.15 per share paid on October 17, 2022.

SEC source: 0001127602-22-024170 · form4.xml · nonDerivative · entry 1

Reidy Christopher R · CIK 0001290907 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,578

F1 · shares: Pursuant to restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 17, 2022, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $48.81. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-22-024168 · form4.xml · nonDerivative · entry 1

CHIDSEY JOHN · CIK 0001128484 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 155,253

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 17, 2022, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $48.81. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-22-024124 · form4.xml · nonDerivative · entry 1

Williams Terrance · CIK 0001798480 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,070

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 17, 2022, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $48.81. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-22-024122 · form4.xml · nonDerivative · entry 1

SCHLICHTING NANCY M · CIK 0001376358 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,001

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 17, 2022, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $48.81. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-22-024120 · form4.xml · nonDerivative · entry 1

O'Connor Kevin J. · CIK 0001808321 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,961

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 17, 2022, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $48.81. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.

SEC source: 0001127602-22-024118 · form4.xml · nonDerivative · entry 1

Maryland Patricia Anne · CIK 0001798468 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,716

F1 · shares: Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments. The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 17, 2022, Encompass Health paid a dividend on its common stock of $0.15 per share and the closing price was $48.81. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.